New imaging agent could spot prostate cancer spread

NCT ID NCT03334500

Ongoing Diagnosis Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new radioactive tracer called 18F-FTT in 30 men with prostate cancer. The tracer is designed to light up PARP-1 activity on PET/CT scans, which may help doctors see where cancer has spread. Researchers will compare the scan results with tissue samples to see if the tracer works well. The main goal is to check safety and see if this imaging method is feasible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-FluorThanatrace (18F-FTT), a radioactive tracer for PET/CT imaging
What this could lead to: If successful, this could lead to a better way to see prostate cancer spread using a special PET scan, helping guide treatment decisions.
What could go wrong: This is a very early, small study (30 people) focused on safety and imaging accuracy, not treatment. The tracer may not reliably detect all tumors, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.